Drug intelligence / Profile preview

AZD4954

Development stage: Phase 1
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

AZD4954 is an investigational small molecule drug developed by AstraZeneca, currently in Phase 1 clinical trials. It is being studied for the treatment of individuals with elevated lipoprotein(a) (Lp(a)) levels, a recognized risk factor for cardiovascular disease. The mechanism of action has not been disclosed, but the primary goal of current studies is to evaluate the drug’s safety, tolerability, pharmacokinetics, and pharmacodynamics following single and multiple ascending dose administration in healthy adults and those with high Lp(a)[1][3][4][5][6][7][8][9]. The drug is administered orally and trials are placebo-controlled. There are no approved specific therapies for high Lp(a), making AZD4954 a potential first-in-class therapy in this area.

Other names: AZD4954AZD-4954AZD 4954

Beyond the preview

Go deeper on AZD4954.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD4954.

Explore the full profile